Annak eldöntésében segít, hogy szükség van-e a prosztatarák kimutatását célzó újabb prosztata biopsziára.
Amikor egy 50 év feletti férfinél egy vagy több korábbi negatív biopszia után az orvos újabb prosztata biopsziát fontolgat.
Szakorvos által végzett digitális rektális vizsgálat (a végbélen keresztül ujjal történő prosztatamasszázs) után gyűjtött első vizelet.
Nincs szükség előkészületre.
(2018 April 5). Prostate Cancer Early Detection. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) Version 2.2018. Available online at https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf Accessed on 04/07/18.
Strong, A. and Deane, L. (2017). Contemporary Role of Biomarkers In the Evaluation, Stratification, And Treatment Determination in Men at Risk for and/or Diagnosed With Prostate Cancer. Urol Nurs. 2017;37(4):192-203. Urologic Nursing. Available online at https://www.medscape.com/viewarticle/892905. Accessed on 04/07/18.
Ashley, V.A. et. al. (2017). The Use of Biomarkers in Prostate Cancer Screening and Treatment. Rev Urol. 2017;19(4):221-234. Available online at https://www.ncbi.nlm.nih.gov/pubmed/29472826. Accessed on 04/07/18.
NCI Staff. (2017 June 9). Biomarker Test Could Reduce Unnecessary Biopsies to Detect Prostate Cancer. National Cancer Institute. Available online at https://www.cancer.gov/news-events/cancer-currents-blog/2017/biomarkers-urine-prostate-biopsy. Accessed on 04/07/18.
Genzen, J. et. al. (2018 April, Updated). Prostate Cancer – PSA. ARUP Consult. Available online at https://arupconsult.com/content/prostate-cancer. Accessed on 04/07/18.
(2015). Early Detection of Prostate Cancer. American Urological Association. Available online at https://www.auanet.org/guidelines/early-detection-of-prostate-cancer-(2013-reviewed-and-validity-confirmed-2015). Accessed on 04/07/18.
Deng, J. et. al. (2017 March 7). Long Non-Coding RNA as Potential Biomarker for Prostate Cancer: Is It Making a Difference? Int J Environ Res Public Health. 2017 Mar; 14(3): 270. Available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369106/. Accessed on 04/07/18.
(© 1995–2018). PCA3 (Prostate Cancer Antigen 3). Mayo Clinic Mayo Medical Laboratories. Available online at https://www.mayomedicallaboratories.com/test-catalog/Overview/75211. Accessed on 04/07/18.
(2018 January 4, Updated). Key Statistics for Prostate Cancer. American Cancer Society. Available online at https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. Accessed on 04/07/18.
(2018 February 22, Updated). Prostate Cancer Screening (PDQ®)-Patient Version. National Cancer Institute. Available online at https://www.cancer.gov/types/prostate/patient/prostate-screening-pdq#section/_13. Accessed on 04/07/18.
Cheuck, L. et. al. (2017 September 21, Updated). Prostate Cancer Diagnosis and Staging. Medscape Urology. Available online at https://emedicine.medscape.com/article/458011-overview. Accessed on 04/07/18.
Chunhua, L. et. al. (2018 March 21). Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer. Transl Oncol. 2018 Mar 21;11(3):628-632. Available online at https://www.ncbi.nlm.nih.gov/pubmed/29574327. Accessed on 04/07/18.
Davenport, L. (2015 January 12). Questions Remain Over Role of PCA3 Assay in Prostate Cancer. Medscape Oncology News. Available online at https://www.medscape.com/viewarticle/837934. Accessed on 04/07/18.
Reuters Staff. (2017 May 25). Urinary RNA Testing Helps Identify Aggressive Prostate Cancer. Medscape News. Available online at https://www.medscape.com/viewarticle/880543. Accessed on 04/07/18.
Feng, F. et. al. (2014). Current and Future Applications Of Genetic Prostate Cancer Screening in the Urologic Clinic. Urol Nurs.2014;34(6):281-291. Available online at https://www.medscape.com/viewarticle/840844. Accessed on 04/07/18.